Research Paper Volume 12, Issue 14 pp 14649—14676

Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non–small-cell lung carcinoma

class="figure-viewer-img"

Figure 5. Correlation of DNAm-based risk score with TMB, cell cycle, DNA damage response (DDR) genes. (A) Left, TMB estimation of TCGA NSCLC patients in high- and low-risk group; right, GSVA presenting DDR pathways significantly enriched in high risk group (adjusted P < 0.01). (B) Estimated frequencies of mutations in TP53 (top left), STK11 and DDR genes (top right), TP53/KRAS co-mutations and TP53-Mut/EGFR-Wt mutations (bottom) under different recurrence risk status. (C) Protein expression of ATM, PARP1, PCNA and CYCLINE1 associated with DNAm-based risk score in TCGA cohort.